Corporate Profile
ImVisioN Therapeutics Inc. is a biotechnology company that is pioneering the use of intralymphatic immunotherapy (ILIT ™) to develop safe, effective and convenient treatments for major allergies.
ImVisioN’s lead product, IVN201, is a MAT ™ immunotherapeutic that targets cat dander allergy, a common allergy inadequately addressed by available therapeutic interventions. ImVisioN also has programes to target birch pollen and house dust mite allergies, two of the most common allergies in man. Over half of all allergic patients in the developed world suffer from one of the three allergies targeted by ImVisioN.
ImVisioN Therapeutics AG was incorporated in Muttenz, Switzerland in August 2008 when it also acquired ImVisioN GmbH, which had originally been founded in January 2005 in Hanover, Germany.